U.S. Organ-on-a-Chip Market

Market Definition

The organ-on-a-chip (OOC) market comprises micro-engineered cell culture platforms that replicate the structural, mechanical, and biochemical environment of human organs using living cells. These systems provide a more physiologically relevant alternative to conventional 2D cell cultures and animal models for studying human biology. The market ecosystem includes the consumption of individual OOC chips, instruments, consumables, accessories, and software supporting applications in drug discovery, disease modeling, toxicity testing, and personalized medicine.

U.S. Organ-on-a-Chip (OOC) Market Overview

The U.S. organ-on-a-chip market was valued at USD 172.9 million in 2025 and is estimated to grow from USD 215.37 million in 2026 to USD 869.1 million by 2033, registering a CAGR of 24.34% over the forecast period (2026-2033). The growing demand for accurate human-relevant alternatives to traditional animal testing is creating significant growth avenues. The ability of OOCs to leverage microfluidics to simulate human organ functions, thereby reducing drug development costs and lowering clinical trial failure rates, is boosting market development.

Major companies operating in the market, including AlveoliX AG, Axion BioSystems, Inc., BioIVT, CN Bio Innovations Ltd., Emulate Inc., InSphero, Mimetas B.V., and Quris Technologies LTD., are forming strategic partnerships with technology providers and investment companies to expand their market reach.

• In November 2025, Emulate partnered with FUJIFILM Cellular Dynamics to launch the Brain-Chip R1, a human-relevant organ-on-a-chip model designed to improve neurological drug development. The platform replicates the human neurovascular unit and blood-brain barrier using five human iPSC-derived cell types, enabling more accurate evaluation of drug transport and neuroinflammation.

Key Market Highlights

1. The U.S. organ-on-a-chip market size was USD 172.9 million in 2025.
2. The market is projected to grow at a CAGR of 24.34% from 2026 to 2033.
3. The others chip type segment captured the highest share of 35.92% in 2025, with a valuation of USD 62.0 million.
4. The product type segment garnered USD 112.5 million in revenue in 2025.
5. The instrument segment accounted for the largest share of 49.16% in 2025, registering a valuation of USD 55.3 million.
6. The personalized medicine segment is anticipated to grow at the fastest CAGR of 26.12% over the forecast period, reaching USD 75.9 million by 2033.
7. The contract research organizations segment is likely to register a CAGR of 26.47% over the forecast period (2026-2033).

How does the inability of animal models to accurately mimic human physiology accelerate the adoption of organ-on-a-chip systems (OOCs)?

The inability of animal models to accurately replicate human physiology at molecular and cellular levels boosts the adoption of OOCs in drug discovery and pharmaceutical research. Animal models often fail to reliably predict human health and exhibit poor safety and efficacy in human trials, which restricts their effectiveness in drug discovery and pharmaceutical research.

Compounds that appear safe in animals may cause adverse effects in humans owing to differences in metabolism, immune responses, receptor biology, and tissue susceptibility. For instance, the antiviral compound Fialuridine (FIAU), despite passing animal testing, caused fatal hepatic failure and lactic acidosis in human trials. Conversely, potentially effective drugs may be rejected due to species-specific toxicity, as seen with penicillin, which is life-saving in humans but toxic to guinea pigs.

The limitations increase the demand for preclinical testing platforms such as OOCs, which replicate human tissue structure and function, enabling physiologically relevant data generation and reducing late-stage clinical failures.

• In July 2025, the U.S. National Institute of Health (NIH) restricted funding for new animal-based research proposals and prioritized human-relevant methodologies. 

• In April 2025, the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing requirements for certain drugs, promoting alternatives such as AI-based models, organoids, and organ-on-a-chip technologies. 

• In April 2024, CN Bio secured USD 21 million to expand its organ-on-a-chip (OOC) product portfolio and global operations, driven by rising demand for human-relevant preclinical models and evolving regulatory support.

How does the relatively short culture lifespan of OOC technology limit the growth of the U.S. organ-on-a-chip market?

The relatively short culture lifespan of the organ-on-a-chip technology stems from the tendency of cultured organ cells to lose physiological characteristics, resulting in reduced reliability and reproducibility of experimental outcomes. OOCs maintain viable, functional tissue models for only days to weeks, whereas many biological processes, disease progressions, and drug development studies require long-term observation spanning months or years. This limitation restricts the ability of OOCs to model chronic diseases, assess long-term drug toxicity, and study extended developmental processes.

Additionally, the cellular system in the OOC recapitulates the interaction of cells/tissue with blood and circulating substances, which mandates a reliable fluidic circuit that ensures stable fluid flow. The process results in the formation of bubbles in the microfluidic channels, adversely affecting culture conditions and leading to variability in cell population densities.

To address the challenge, market players are adopting strategies to extend culture longevity in order to enable the study of slow-developing diseases such as neurodegeneration, fibrosis, and cancer metastasis, which remain difficult to assess using short-term models. 

• In October 2025, CN Bio introduced PhysioMimix Core, featuring recirculating media and adjustable inter/intra-organ flow rates to maintain biomarker levels. This enables long-term studies, including repeat dosing and chronic disease modeling.

How is the adoption of body-on-chip (BOC) systems emerging as a notable trend in the U.S. organ-on-a-chip market?

Body-on-a-chip (BOC) platforms are developed by integrating multiple organ-on-chip (OOC) systems to recapitulate interactions between different tissues. BOCs represent miniature human body systems, typically comprising two or more interconnected multi-organ chip platforms. This enables the replication of key aspects of human physiology and the simulation of interactions between administered drugs and multiple organs. The critical role of tissue-to-tissue crosstalk in disease initiation and progression is further driving the development of BOC platforms that incorporate a recirculating shared medium.

BOCs integrate multiple organ units, including gut (absorption), liver (metabolism), and kidney (elimination), within a single chip, enabling coordinated communication among organ components while allowing each organ model to retain its physiological identity and function. This enhances the replication of systemic human physiology, including inter-organ interactions, drug metabolism, and disease progression, thereby improving the prediction of drug efficacy and toxicity compared to standalone organ models.

• In July 2026, MIT researchers built a human blood vessel on a chip, which is composed of a central artery made from human endothelial cells and is embedded in a gel containing a small magnet.

• In June 2025, Emulate launched the AVA Emulation System, a next-generation 3-in-1 Organ-Chip platform designed for high-throughput applications. The system combines microfluidic control across 96 Organ-Chip “Emulations” with automated imaging and a self-contained incubator, enabling scalable, reproducible data generation for pharmaceutical and translational research. 

Organ-on-a-Chip Market Report Snapshot

Market Segmentation

• By Chip Type (Liver-on-a-Chip, Heart-on-a-Chip, Kidney-on-a-Chip, Lungs-on-a-Chip, and Others): The liver-on-a-chip segment accounted for the largest share of 29.87% in 2025, valued at USD 51.64 million. The widespread prevalence of non-alcoholic fatty liver disease (NAFLD) and other chronic liver disorders is driving demand for advanced in vitro liver models for disease research and drug development. 

• By Type (Product and Services): The product segment generated USD 112.5 million in 2025, accounting for the highest share of 65.09%. The high demand for OOC chips embedded with microscopic hollow channels lined with living cells to mimic specific human organs supports segmental growth. 

• By Product (Instrument, Consumables and Accessories, and Software): The instruments segment held the largest share of 49.16% in 2025, valued at USD 55.3 million. This growth is supported by high-resolution fluorescence imaging systems, microfluidic pumping instruments, and automated liquid-handling stations. 

• By Application (Personalized Medicine, Drug Discovery, Disease Modelling, Toxicity Testing, and Others): The personalized segment is anticipated to register the fastest growth rate of 26.12% over the forecast period, reaching USD 75.9 million by 2033. Surging demand for tailored treatments for specific diseases based on individual genetic profiles fosters this rapid growth. 

• By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, Cosmetics and Personal Care Industry, and Others): The contract research organizations segment is expected to grow at the fastest CAGR of 26.47% over the forecast period (2026-2033). This growth is fueled by the ability of CROs to offer highly predictive, human-specific preclinical testing services. 

What is the market scenario in the U.S. organ-on-a-chip market?

The U.S. remains a global leader in drug innovation and clinical research. The rise in demand for novel therapies, precision medicine, personalized healthcare, toxicology research, and advanced biotech innovations is driving the healthcare sector. Major drivers of the OOC market in the U.S. include strong R&D investment, expanding biotechnology innovation, and rising demand for advanced therapies. A robust healthcare infrastructure, diverse patient pool, and experienced research workforce boost trial efficiency, thus accelerating regional market expansion.

Moreover, a supportive regulatory landscape that restricts conventional animal testing and facilitates the adoption of New Approach Methodologies (NAMs) is propelling OOCs adoption. Additionally, strategic government-led initiatives supporting the use of organ-on-a-chip technology in advanced biomedical and space health research are accelerating innovation and expanding commercial potential. 

• In September 2025, NASA announced the AVATAR investigation under the Artemis II mission to evaluate the effects of deep space radiation and microgravity on human health using personalized organ-on-a-chip technology. The initiative is anticipated to advance precision medicine, radiation research, and drug development, thereby strengthening the commercial and scientific potential of organ-on-a-chip technology for both space exploration and terrestrial healthcare applications. 

Regulatory Frameworks

• The U.S. Food and Drug Administration (FDA) Modernization Act 2.0 provides guidelines for eliminating animal testing. The agency recognizes organ-on-chip and microphysiological systems, along with other alternatives, for generating drug safety and efficacy data. 

• The Good Laboratory Practice (GLP) Regulations issued by the U.S. FDA establish quality standards for nonclinical laboratory studies. The regulation supports research and marketing applications for FDA-regulated products, including drugs, biologics, medical devices, food additives, and other healthcare products, and applies to both in vivo and in vitro nonclinical studies. 

Competitive Landscape

Companies operating in the U.S. organ-on-a-chip market are expanding operations through strategic partnerships and securing funding from venture capital and government agencies, including the U.S. National Institutes of Health (NIH) and the U.S. Department of Defense, driven by regulations supporting the phased reduction of animal testing. Companies with strong financial positions, established partnerships, and validated OOC products are anticipated to achieve steady growth in the competitive market.

• In April 2026, Oregon Health & Science University (OHSU) secured USD 2 million in NIH funding to advance next-generation organ-on-a-chip technologies for studying bone-related cancers.

Key Companies in the U.S. Organ-on-a-Chip Market

• AlveoliX AG
• Axion BioSystems, Inc.
• Beonchip
• BioIVT
• Cherry Biotech
• CN Bio Innovations Ltd
• Elveflow
• Emulate Inc.
• InSphero
• Kirkstall Ltd
• Mimetas B.V.
• Netri
• Quris Technologies LTD.
• TissUse GmbH
• 4Dcell

 Recent Developments

• In February 2026, researchers at MIT developed a new type of tissue model that accurately mimics the architecture of the liver, including blood vessels and immune cells. The development aims to address metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by a buildup of fat in the liver. 

• In October 2025, researchers at Harvard Wyss Institute introduced a thumb drive-sized uterine model. The initiative aims to support the diagnosis of heavy menstrual bleeding (menorrhagia). 

• In July 2025, 28bio launched Nexon neurotechnology platform, which integrates engineered human brain tissues, neural interfacing, tissue engineering, and AI to improve the prediction of therapeutic efficacy for neurological diseases.